These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12586790)

  • 1. Combination chemotherapy for metastatic breast cancer: reaching for the cure.
    Overmoyer B
    J Clin Oncol; 2003 Feb; 21(4):580-2. PubMed ID: 12586790
    [No Abstract]   [Full Text] [Related]  

  • 2. Improving adjuvant chemotherapy in breast cancer -- can we get more for less with TACT2?
    Johnson L; Cameron D; Barrett-Lee P; Canney P; Bliss JM
    Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):593-5. PubMed ID: 17706405
    [No Abstract]   [Full Text] [Related]  

  • 3. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: the example of clinical studies].
    Sdrobolini A
    Suppl Tumori; 2004; 3(4):S77-8. PubMed ID: 15206220
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trials referral resource. Adjuvant therapy in breast cancer.
    Cheson BD; Phillips PH; Abrams J
    Oncology (Williston Park); 1994 Nov; 8(11):55, 60, 65. PubMed ID: 7826839
    [No Abstract]   [Full Text] [Related]  

  • 5. Improved outcomes from dose-dense adjuvant chemotherapy for breast cancer with growth factor support.
    Leonard JP
    Curr Hematol Rep; 2003 Nov; 2(6):451-2. PubMed ID: 14561387
    [No Abstract]   [Full Text] [Related]  

  • 6. Adjuvant chemotherapy for lymph node-negative, estrogen receptor-negative breast cancer: a tale of three trials.
    Albain KS
    J Natl Cancer Inst; 2004 Dec; 96(24):1801-4. PubMed ID: 15601631
    [No Abstract]   [Full Text] [Related]  

  • 7. Primary chemotherapy regimens and schedules.
    Gradishar WJ
    Semin Oncol; 1998 Apr; 25(2 Suppl 3):25-30. PubMed ID: 9566204
    [No Abstract]   [Full Text] [Related]  

  • 8. [Place of high-dose therapy in breast cancer. Austrotransplant consensus conference 1999].
    Greinix H
    Wien Klin Wochenschr; 2000 Jul; 112(13):601-3. PubMed ID: 11001746
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer.
    Hryniuk W
    J Natl Cancer Inst; 1999 Aug; 91(16):1425. PubMed ID: 10451457
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequential single-agent chemotherapy for metastatic breast cancer: therapeutic nihilism or realism?
    Seidman AD
    J Clin Oncol; 2003 Feb; 21(4):577-9. PubMed ID: 12586789
    [No Abstract]   [Full Text] [Related]  

  • 11. High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: the jury is still out.
    Smith GA; Henderson IC
    Important Adv Oncol; 1995; ():201-14. PubMed ID: 7672807
    [No Abstract]   [Full Text] [Related]  

  • 12. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [High-dose chemotherapy in breast cancer].
    Schmid P; Possinger K
    Med Klin (Munich); 2002 Nov; 97(11):677-86. PubMed ID: 12434276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant chemotherapy for operable breast cancer.
    Green M; Hortobagyi GN
    Oncology (Williston Park); 2002 Jul; 16(7):871-84, 889; discussion 889-90, 892-4, 897-8. PubMed ID: 12164555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?
    Crown J
    Lancet; 2003 Aug; 362(9385):677-8. PubMed ID: 12957087
    [No Abstract]   [Full Text] [Related]  

  • 16. Timed-flat infusion of 5-fluorouracil associated with docetaxel as first-line treatment of patients with metastatic breast cancer.
    Rispoli AI; Morelli MF; Ricevuto E; Cannita K; Santomaggio A; Mancini M; Tudini M; Cianci G; Porzio G; Lanfiuti Baldi P; Di Rocco CZ; Tinari N; Iacobelli S; Marchetti P; Ficorella C
    Breast J; 2008; 14(1):116-7. PubMed ID: 18086273
    [No Abstract]   [Full Text] [Related]  

  • 17. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Chemotherapy: what kind of evidence?].
    Baldini E; Prochilo T
    Suppl Tumori; 2004; 3(4):S79-80. PubMed ID: 15206221
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose chemotherapy in metastatic breast cancer.
    Basade MM; Gulati SC
    Lancet; 1998 Feb; 351(9100):386-7. PubMed ID: 9482287
    [No Abstract]   [Full Text] [Related]  

  • 19. [High doses of chemotherapy in the treatment of breast cancer: the current prospects].
    Martin M; Livingston RB
    Rev Clin Esp; 1993 May; 192(8):400-7. PubMed ID: 8511380
    [No Abstract]   [Full Text] [Related]  

  • 20. [The use of high-dose chemotherapy in the treatment of breast cancer].
    Espinosa E; Zamora P; González Barón M
    Med Clin (Barc); 1996 Jun; 107(2):56-8. PubMed ID: 8753896
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.